Celldex Therapeutics (CLDX)
(Real Time Quote from BATS)
$33.74 USD
-0.48 (-1.40%)
Updated May 30, 2024 02:49 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Celldex Therapeutics, Inc. [CLDX]
Reports for Purchase
Showing records 401 - 411 ( 411 total )
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of October 2.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals/BioDefense: September 2011 Potential Milestones & Key Events - Monthly Update.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:11 Results - Rindopepimut Pivotal Trial to Start YE:11, Initial Data Potentially at ASCO 2012
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1:11 Results - Phase IIb of CDX-011 in Refractory Breast Cancer Enrolling Well
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 3
Provider: WEDBUSH SECURITIES INC.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4:10 Update - Initiation of a PIII Rindopepimut GBM Study and PIIb CDX-011 Breast Cancer
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rindopepimut ACTIII Phase II Study Meets Primary Endpoint, Raising Price Target to $5.75
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Research Coverage with an OUTPERFORM Rating and $5.25 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G